Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL959919 | 0.85 | HDAC6 (0.34) | HDAC6HDAC1HDAC2CA14 | |
| SCHEMBL15326145 | 0.82 | HDAC6 (0.37) | HDAC6HDAC1HDAC2CA14 | |
| SCHEMBL963261 | 0.74 | HDAC6 (0.38) | HDAC6HDAC1HDAC2CA14 | |
| SCHEMBL8670353 | 0.72 | CA14 (0.35) | CA14 | |
| SCHEMBL8670355 | 0.72 | — | — | |
| SCHEMBL31011754 | 0.71 | CA14 (0.47) | HDAC6HDAC1HDAC2CA14 | |
| SCHEMBL14989138 | 0.70 | CA14 (0.30) | CA14 | |
| SCHEMBL8693203 | 0.70 | SLC7A5 (0.36) | — | |
| SCHEMBL25795585 | 0.70 | HDAC6 (0.36) | HDAC6HDAC1HDAC2CA14 | |
| SCHEMBL8697011 | 0.69 | CA14 (0.37) | HDAC6HDAC1HDAC2CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050025740-A1 | Polyoxime compounds and their preparation | AMYLIN PHARMACEUTICALS, INC. | 2005-02-03 | — | — | US | disclosed |
| US-6663869-B1 | Linkages between polypeptide organic molecules are oxime linkages formed by reaction of a keto, aldehyde or amino-oxy group on the amino acid | GRYPHON THERAPEUTICS, INC. | 2003-12-16 | — | — | US | disclosed |
| US-6217873-B1 | HOMOGENEOUS; MEDICAL DIAGNOSIS | GRYPHON SCIENCES | 2001-04-17 | — | — | US | disclosed |
| EP-0697891-B1 | POLYOXIME COMPOUNDS AND THEIR PREPARATION | ROSE KEITH (CH) | 2000-03-29 | — | — | EP | disclosed |
| EP-0697891-A1 | POLYOXIME COMPOUNDS AND THEIR PREPARATION | Rose, Keith (CH) | 1996-02-28 | — | — | EP | disclosed |
| WO-1994025071-A1 | POLYOXIME COMPOUNDS AND THEIR PREPARATION | ROSE KEITH (CH) | 1994-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050025740-A1 | Polyoxime compounds and their preparation | PCBP1, PAM, OGFOD1 | HDAC6 4315/4885HDAC1 4817/4885HDAC2 4457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.